Quarterly Report • Jun 30, 2015
Quarterly Report
Open in ViewerOpens in native device viewer
Condensed consolidated interim financial statements
For the six months period ended 30 June 2015
Registered office: C/O Capita Company Secretarial Services 1st Floor, 40 Dukes Place, London, EC3A 7NH
The Group performed well in the six months to 30 June 2015 and largely in line with management expectations. Significant revenue growth in the period came from recent strategic developments and, in particular, the Al Madar Medical Centre network, offsetting the effects of our repositioning of Khalifa Street and of new competition entering the market. We operate in one of the fastest growing sectors in the Gulf region, due to a rapidly ageing demographic, an increasing incidence of lifestyle-related medical conditions such as diabetes and obesity, and service gaps in the current healthcare market. These underlying fundamentals and our strong brand justify our continued investment in our hospitals and outpatient medical centre network, as well as in top quality clinical staff and state-of the art medical equipment.
During the period, Group revenue increased by 8.5% to US\$244m compared to H1 2014. Underlying EBITDA increased to US\$53.9m, up 4.3%, with EBITDA margin declining to 22.1% from 23.0% in H1 2014. Underlying Net Profit declined by 0.5% to US\$45.4m.
The improved revenue was primarily driven by higher outpatient volumes, up 13% on H1 2014, largely arising from the performance of our new medical centres and growth in patient volumes from our acquired facilities. This offset the impact of the refurbishment and repositioning programme at Khalifa Street Hospital, which saw its revenues reduce by 12% in the period.
Our strategy of investing in our inpatient business has started to yield positive results with volumes growing by 6.9%, despite the decline in volume at Khalifa Street Hospital.
We delivered volume growth across all insurance payer categories. Average revenue per inpatient increased by 0.4%, while average outpatient revenue decreased by 3%. The decline in the average revenue per outpatient visit was primarily due to a change in payer mix, with faster growth in Abu Dhabi Basic plan patients and a reduction in ancillary tests.
The reduction in underlying EBITDA margin was primarily the result of the decrease in patient volumes at Khalifa Street Hospital. As mentioned previously, we are executing a robust repositioning plan focusing on building back patient volumes lost to increased competition, upgrading our facility and equipment and reducing our costs to match current activity levels. The hospital is located in a prime location in the heart of Abu Dhabi, and has a long history and positive reputation for serving the community. We expect to see the financial benefits of our reinvestment materialize in late 2016, and build strongly from 2017 onwards.
EBITDA margins were also impacted by a one-off negative adjustment to consumables and medicine stocks due to better visibility with our new materials management systems in addition to advisory expenses. These factors resulted in one-off costs of nearly \$2 million in the first half.
Although performing well, the new start-up medical centres are not yet at capacity and continued to suppress margins during the period. We typically see our new medical centres reach margin maturity within 2-3 years from opening.
The decline in Underlying Net profit was due to the factors stated above, and higher depreciation expenses of \$2.7 million arising from our investments in the past year in new medical centres, patient room renovations, large-scale imaging equipment as well as the acquisition of our cancer centre, GICC. We expect to deliver higher earnings on these investments as they mature and as GICC becomes more fully integrated in to our healthcare system.
| Operating KPI's | H1 2015 | H1 2014 | Change % |
|---|---|---|---|
| Out Patient Visits1 | 1,142,100 | 1,009,323 | 13.2% |
| Average revenue per out-patient (US\$)2 | 163 | 168 | -3.2% |
| Out-patient revenues (US\$, m)3 | 189.8 | 174.3 | +8.9% |
| In-patient admissions4 | 22,205 | 20,771 | +6.9% |
| Average revenue per in-patient (US\$) | 2,441 | 2,431 | +0.4% |
| In-patient revenues (US\$, m) | 54.2 | 50.5 | +7. 3% |
| Total revenue (US\$, m) | 244.0 | 224.8 | +8.5% |
1 Excludes follow-up visits
2 Includes Net revenue from provision of medical and hospital services, laboratory, radiology and pharmacy services and excludes Projects revenue, Commercial dept. revenue, and Other Misc. Income
3 Includes revenues from Projects, Commercial Division, and other miscellaneous income.
4 Includes DRG, Day Case, short stay, new born and LTC
On 24 August, 2015, the Group received shareholder approval for its plans to lease additional land and premises to expand operations at Al Ain Hospital, Khalifa Street Hospital and Airport Road Hospital. This allows us to deliver on our strategy of leveraging the Group's asset base to take advantage of the strength of the Abu Dhabi healthcare market.
The additional space will allow the Group to build on its position as the largest private integrated healthcare system in the Abu Dhabi Emirate by significantly expanding capacity and service offerings across all three hospitals:
During the first six months, we continued to increase access points into our integrated system. For example, the Emirates Nuclear Energy Company clinic in the Western Region, which serves nearly 15,000 employees working at the nuclear power plant, is now open and fully operational. We remain on track to open new medical centres by the end of the year in Sharjah, the second fastest growing Emirate, and in the city of Al Ain.
During the period, we continued our successful recruitment of high-quality clinical staff to meet the growth in our medical centre network and hospitals. Recruiting and retaining high-quality medical and clinical staff is a clear competitive advantage for the Group. At the same time, management has been able to operate the expanding facilities with only a slight increase in administrative staff comparing H1 2015 with H1 2014.
| Personnel KPIs | H1 2015 | H1 2014 | Change |
|---|---|---|---|
| No. of Doctors | 684 | 610 | 12.1% |
| No. of Nursing staff | 908 | 803 | 13.1% |
| No. of Other Medical Staff | 829 | 729 | 13.7% |
| No. of Admin Support Staff | 1,769 | 1,750 | 1.1% |
Joanne Curin was appointed in late July as the interim Chief Financial Officer to lead the Company's experienced financial team. The international search for a permanent CFO is well underway and a further announcement will be made in due course.
The Group remains in an extremely strong financial position. At the end of June 2015 it was debt free, with a cash balance of US\$77.2m and short term deposits of US\$13.8m. The Group's cash reserves continue to grow, giving it a strong platform from which to invest in organic and inorganic growth.
The Board has reviewed the results for the first six months and determined on 24 August that an interim dividend of GBP 4.1 pence per share for 2015 (compared to GBP 3.7 pence in 2014) be paid on 5 October 2015 to all ordinary shareholders who were on the register at the close of business on 4 September 2015.
We expect to deliver slightly higher growth in revenue and earnings in the second half compared with the first six months of the year, as we increase the number of inpatient beds in Al Ain Hospital, gain the benefits of recent investments in infrastructure and equipment at our hospitals and continue to increase patient visits to the medical centres opened in 2014, as well as capture further growth from acquired medical centres.
Alongside these volume building strategies, the new management team has recently implemented a number of margin improvement initiatives such as improving the productivity of clinical and administrative staff and enhancing procurement practices. Early benefits from these are expected to offset losses from start-up medical centres and the slight decrease in average outpatient revenue per encounter.
The principal risks facing the Group for the remaining six months of the financial year are expected to be the same as those reported on pages 38 and 39 of the Annual Report and Accounts 2014 which are recruitment, licensing, and retention of medical staff, mergers and acquisitions, competition, and reputation.
The directors are satisfied that the Group has sufficient resources to continue in operation for a period of not less than 12 months from the date of this report. Accordingly the directors continue to adopt the going concern basis in preparing the condensed financial statements.
The Group's Financial Statements for the half year ended 30th June 2015 are available on the Group's website at www.alnoorhospital.com.
The Interim report is the responsibility of, and has been approved by, the directors. The directors are responsible for preparing the Interim Report in accordance with the Disclosure and Transparency Rules of the United Kingdom's Financial Conduct Authority. The Disclosure and Transparency Rules ("DTR") require that the accounting policies and presentation applied to the quarterly figures must be consistent with those applied in the latest published annual accounts, except where the accounting policies and presentation are to be changed in the subsequent annual accounts, in which case the new accounting policies and presentation should be followed, and the changes and the reasons for the changes should be disclosed in the Interim Report, unless the United Kingdom Financial Conduct Authority agrees otherwise.
We confirm that to the best of our knowledge:
Since the Company's annual report was published on 30 April 2015 there have been two changes to the membership of the board Faisal Belhoul and Khaldoun Haj Hasan resigned from the board.
For and on behalf of the Board of Directors:
Ronald Lavater Chief Executive Officer
24 August 2015
We have been engaged by the company to review the condensed set of financial statements in the halfyearly financial report for the six month ended 30 June 2015 which comprises Condensed consolidated interim statement of financial position, Condensed consolidated interim statement of profit or loss and other comprehensive income, Condensed consolidated interim statement of changes in equity, Condensed consolidated interim statement of cash flows and the related explanatory notes. We have read the other information contained in the half-yearly financial report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements.
This report is made solely to the company in accordance with the terms of our engagement to assist the company in meeting the requirements of the Disclosure and Transparency Rules ("the DTR") of the UK's Financial Conduct Authority ("the UK FCA"). Our review has been undertaken so that we might state to the company those matters we are required to state to it in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company for our review work, for this report, or for the conclusions we have reached.
The half-yearly financial report is the responsibility of, and has been approved by, the directors. The directors are responsible for preparing the half-yearly financial report in accordance with the DTR of the UK FCA. As disclosed in note 1, the annual financial statements of the group are prepared in accordance with IFRSs as adopted by the EU. The condensed set of financial statements included in this half-yearly financial report has been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the EU.
Our responsibility is to express to the company a conclusion on the condensed set of financial statements in the half-yearly financial report based on our review.
We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Auditing Practices Board for use in the UK. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK and Ireland) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the six month ended 30 June 2015 is not prepared, in all material respects, in accordance with IAS 34 as adopted by the EU and the DTR of the UK FCA.
Chartered Accountants 15 Canada Square London E14 5GL
Condensed consolidated interim statement of financial position As at
| 30 June | 31 December | ||
|---|---|---|---|
| 2015 | 2014 | ||
| USD'000 | USD'000 | ||
| Note | (Unaudited) | (Audited) | |
| Non-current assets | |||
| Property and equipment | 4 | 74,160 | 59,057 |
| Intangible assets and goodwill | 5 | 34,389 | 33,177 |
| Prepayments | 8 | 2,480 | 2,534 |
| Deferred tax assets | 269 ----------------------- |
269 ------------------------ |
|
| Total non-current assets | 111,298 ----------------------- |
95,037 ------------------------ |
|
| Current assets | |||
| Inventories | 6 | 19,424 | 20,385 |
| Trade and other receivables | 8 | 124,301 | 115,375 |
| Amount due from a related party | 7(d) | 121 | 851 |
| Short term deposit | 10 | 13,787 | 13,624 |
| Cash and cash equivalents | 9 | 77,211 | 82,881 |
| Total current assets | ----------------------- 234,844 |
----------------------- 233,116 |
|
| Total assets | ----------------------- 346,142 |
----------------------- 328,153 |
|
| ========== | =========== | ||
| Equity | |||
| Share capital | 11 | 18,076 | 18,076 |
| Share premium reserve | 693,549 | 693,549 | |
| Statutory reserve | 4,114 | 4,114 | |
| Merger reserve | (700,009) | (700,009) | |
| Retained earnings | 240,887 | 214,534 | |
| Share option reserve | 3,151 | 3,174 | |
| Equity attributable to the owners of the Company | ----------------------- 259,768 |
-------------------------- 233,438 |
|
| Non-controlling interest | 11 | 6,003 | 4,800 |
| ----------------------- | ----------------------- | ||
| Total equity | 265,771 ----------------------- |
238,238 ------------------------- |
|
| Non-current liabilities | |||
| Trade and other payables | 13 | - | 596 |
| Employee benefits | 14 | 16,117 | 15,377 |
| Total non-current liabilities | ----------------------- 16,117 |
-------------------------- 15,973 |
|
| Current liabilities | ----------------------- | -------------------------- | |
| Trade and other payables | 13 | 58,085 | 67,792 |
| Amounts due to related parties | 7(c) | 6,169 | 6,150 |
| Total current liabilities | ----------------------- 64,254 |
-------------------------- 73,942 |
|
| Total liabilities | ----------------------- 80,371 |
-------------------------- 89,915 |
|
| Total equity and liabilities | ----------------------- 346,142 |
-------------------------- 328,153 |
|
| ========== | =========== |
These condensed consolidated interim financial statements were approved and authorised for issue by the Board of Directors and signed on their behalf on 24 August 2015 by:
Chairman Chief Executive Officer The notes on pages 13 to 23 form an integral part of these condensed consolidated interim financial statements.
| d e de d io 3 0 Ju 2 0 1 5 p er n ne |
d 3 0 Ju 2 0 1 4 ne |
||||||
|---|---|---|---|---|---|---|---|
| de ly ing Un r |
de ly ing No n-u n r |
l To ta |
de ly Un ing r |
de ly No ing n-u n r |
l To ta |
||
| No te |
'0 U S D 0 0 |
'0 U S D 0 0 |
'0 U S D 0 0 |
'0 U S D 0 0 |
'0 U S D 0 0 |
'0 U S D 0 0 |
|
| ( ) Un d ite d au |
( ) Un d ite d au |
( ) Un d ite d au |
( ) Un d ite d au |
( ) Un d ite d au |
( ) Un d ite d au |
||
| Re ve nu e |
1 5 |
2 4 3, 9 7 1 |
- | 2 4 3, 9 7 1 |
2 2 4, 7 8 1 |
- | 2 2 4, 7 8 1 |
| f s les Co st o a |
( ) 1 4 2, 9 9 3 |
- | ( ) 1 4 2, 9 9 3 |
( ) 1 2 6, 3 4 4 |
- | ( ) 1 2 6, 3 4 4 |
|
| f Gr it os s p ro |
------- ------- ------- ------ -- 1 0 0, 9 7 8 |
------- ------- ------- ------ -- - |
------- ------- ------- ------ -- 1 0 0, 9 7 8 |
------- ------- ------- ------ -- 9 8, 4 3 7 |
------- ------- ------- ------ -- - |
------- ------- ------- ------ -- 9 8, 4 3 7 |
|
| l l ing dm in ist ive d o he ing Se rat t t , a an r o p era ex p en se s |
( ) 3 3 8 5 5, ------- ------- ------- ------ |
( ) 0 5 7 ------- ------- ------- ------ |
( ) 8 5 5, 4 5 ------- ------- ------- ------ |
( ) 5 2, 2 0 2 ------- ------- ------- ------ |
- ------- ------- ------- ------ |
( ) 5 2, 2 0 2 ------- ------- ------- ------ |
|
| lts fro Re ing iv it ies t t su m op era ac |
-- 4 5, 6 4 0 |
-- ( ) 5 0 7 |
-- 4 5, 1 3 3 |
-- 4 6, 2 3 5 |
-- - |
-- 4 6, 2 3 5 |
|
| ina F t nc e c os |
( ) 6 3 2 |
- | ( ) 6 3 2 |
( ) 8 6 0 |
- | ( ) 8 6 0 |
|
| ina inc F nc e om e |
3 9 7 ------- ------- ------- ------ |
- ------- ------- ------- ------ |
3 9 7 ------- ------- ------- ------ |
2 5 5 ------- ------- ------- ------ |
- ------- ------- ------- ------ |
2 5 5 ------- ------- ------- ------ |
|
| f Ne ina t t nc e c os |
-- ( ) 2 5 3 |
-- - |
-- ( ) 2 5 3 |
-- ( ) 6 0 5 |
-- - |
-- ( ) 6 0 5 |
|
| f fo he be fo Pro it io d r t tax p er re |
------- ------- ------- ------ -- 4 5, 3 8 7 |
------- ------- ------- ------ -- ( ) 5 0 7 |
------- ------- ------- ------ -- 4 4, 8 8 0 |
------- ------- ------- ------ -- 4 5, 6 3 0 |
------- ------- ------- ------ -- - |
------- ------- ------- ------ -- 4 5, 6 3 0 |
|
| Ta ion t xa |
- | - | - | - | - | - | |
| f fo it he io d Pro r t p er |
------- ------- ------- ------ -- 4 3 8 5, 7 |
------- ------- ------- ------ -- ( ) 0 5 7 |
------- ------- ------- ------ -- 4 4, 8 8 0 |
------- ------- ------- ------ -- 4 6 3 0 5, |
------- ------- ------- ------ -- - |
------- ------- ------- ------ -- 4 6 3 0 5, |
|
| he he ive inc Ot r c om p re ns om e |
=== === === === - |
=== === === === - |
=== === === === - |
=== === === === - |
=== === === === - |
=== === === === = - |
|
| l co he fo he d To ive inc io ta r t mp re ns om e p er |
------- ------- ------- ------ -- 4 5, 3 8 7 |
------- ------- ------- ------ -- ( ) 5 0 7 |
------- ------- ------- ------ -- 4 4, 8 8 0 |
------- ------- ------- ------ -- 4 5, 6 3 0 |
------- ------- ------- ------ -- - |
------- ------- ------- ------ -- 4 5, 6 3 0 |
|
| === === === === |
=== === === === |
=== === === === |
=== === === === |
=== === === === |
=== === === === = |
Condensed consolidated interim statement of profit or loss and other comprehensive income (continued)For six month period ended 30 June 2015
| io d e de d 3 0 Ju 2 0 1 5 p er n ne |
d e de d io 3 0 Ju 2 0 1 4 p er n ne |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| de ly ing Un r |
de ly ing No n-u n r |
l To ta |
de ly ing Un r |
de ly ing No n-u n r |
l To ta |
||||
| No te |
'0 U S D 0 0 |
'0 U S D 0 0 |
'0 U S D 0 0 |
'0 U S D 0 0 |
'0 U S D 0 0 |
'0 U S D 0 0 |
|||
| ( d ite d ) Un au |
( d ite d ) Un au |
( d ite d ) Un au |
( d ite d ) Un au |
( d ite d ) Un au |
( d ite d ) Un au |
||||
| f it a i bu b le Pr ttr ta to o : |
|||||||||
| f t he Ow Co ne rs o mp an y |
4 2, 5 6 3 |
( ) 5 0 7 |
4 2, 0 5 6 |
4 4, 5 0 6 |
- | 4 4, 5 0 6 |
|||
| l l No ing int tro st n-c on ere |
1 1 |
2, 8 2 4 |
- | 2, 8 2 4 |
1, 1 2 4 |
- | 1, 1 2 4 |
||
| f fo he d Pro it io r t p er |
------- ------- ------- ------ -- 4 5, 3 8 7 |
------- ------- ------- ------ -- ( ) 5 0 7 |
------- ------- ------- ------ -- 4 4, 8 8 0 |
------- ------- ------- ------ -- 4 5, 6 3 0 |
------- ------- ------- ------ -- - |
------- ------- ------- ------ -- 4 5, 6 3 0 |
|||
| l c he ive inc i bu b le To ta ttr ta to om p re ns om e a : |
=== === === === |
=== === === === |
=== === === === |
=== === === === |
=== === === === |
=== === === === = |
|||
| f t he Ow Co ne rs o mp an y |
4 2, 5 6 3 |
( ) 5 0 7 |
4 2, 0 5 6 |
4 4, 5 0 6 |
- | 4 4, 5 0 6 |
|||
| l l ing int No tro st n-c on ere |
1 1 |
2, 8 2 4 |
- | 2, 8 2 4 |
1, 1 2 4 |
- | 1, 1 2 4 |
||
| f fo he d Pro it io r t p er |
------- ------- ------- ------ -- 4 5, 3 8 7 |
------- ------- ------- ------ -- ( ) 5 0 7 |
------- ------- ------- ------ -- 4 4, 8 8 0 |
------- ------- ------- ------ -- 4 5, 6 3 0 |
------- ------- ------- ------ -- - |
------- ------- ------- ------ -- 4 5, 6 3 0 |
|||
| ing ha Ea rn s p er s re : |
=== === === === |
=== === === === |
=== === === === |
=== === === === |
=== === === === |
=== === === === = |
|||
| ha ( ) Ba ic e ing nts s arn s p er s re ce |
1 7 |
3 6. 0 |
3 8. 1 |
||||||
| ( ) i lut d e ing ha D nts e arn s p er s re ce |
1 7 |
=== === === === 3 9 5. |
=== === === === = 3 9 7. |
||||||
| === === === === |
=== === === === = |
The notes on pages 13 to 23 form an integral part of these condensed consolidated interim financial statements.
Condensed consolidated interim statement of changes in equity For six month period ended 30 June 2015
| trib ble uit ha reh old of th At e C uta to eq y s ers om pa ny |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sh are |
No n- |
||||||||
| Sh are |
mi pre um |
Sta tut ory |
Me rge r |
d Re tai ne |
Sh tio are op n |
llin tro con g |
tal To |
||
| ita l cap |
res erv e |
res erv e |
res erv e |
rni ea ng s |
res erv e |
tal To |
int st ere |
uit eq y |
|
| US D'0 00 |
US D'0 00 |
US D'0 00 |
US D'0 00 |
US D'0 00 |
US D'0 00 |
US D'0 00 |
US D'0 00 |
US D'0 00 |
|
| ( 11) No te |
( 11) No te |
||||||||
| ( ) At 1 J 20 15 Au dit ed an ua ry |
18, 07 6 -------- -------- --- |
69 3, 54 9 -------- -------- |
4, 114 -------- -------- |
( ) 70 0, 00 9 -------- -------- |
214 53 4 , -------- -------- |
3, 174 -------- -------- |
23 3, 43 8 -------- -------- |
4, 80 0 -------- -------- |
23 8, 23 8 -------- -------- |
| Tot al c he nsi inc om pre ve om e: |
------ | ----- | ------- | ----- | ----- | ----- | ----- | ---- | |
| fit for Pro th eri od e p |
- | - | - | - | 42 05 6 , |
- | 42 05 6 , |
2, 82 4 |
44 88 0 , |
| -------- -------- --- |
-------- -------- ------ |
-------- -------- ----- |
-------- -------- ------- |
-------- -------- ----- |
-------- -------- ----- |
-------- -------- ----- |
-------- -------- ----- |
-------- -------- ---- |
|
| tal reh To siv e i co mp en nco me |
- | - | - | - | 42 05 6 , |
- | 42 05 6 , |
2, 82 4 |
44 88 0 , |
| f th Tra cti ith e C nsa on s w ow ne rs o om pa ny : ibu tio nd di ibu tio Co ntr str n a ns: |
|||||||||
| ity tle d s ha bas ed Ne t e set nt qu re- pay me |
- | - | - | - | - | ( ) 23 |
( ) 23 |
- | ( ) 23 |
| ide nd aid (re fer d 1 1) Div 12 te s p no an |
- | - | - | - | ( ) 15, 70 3 |
- | ( ) 15, 70 3 |
( 1) 1, 62 |
( ) 17, 324 |
| ( dit ed ) At 30 Jun e 2 01 5 Un au |
-------- -------- --- 18, 07 6 ==== ==== = |
-------- -------- ------ 69 3, 54 9 ==== ==== == |
-------- -------- ----- 4, 114 ==== ==== = |
-------- -------- ------- ( ) 70 0, 00 9 ==== ==== == |
-------- -------- ----- 24 0, 88 7 ==== ==== = |
-------- -------- ----- 3, 15 1 ==== ==== = |
-------- -------- ----- 25 9, 76 8 ==== ==== = |
-------- -------- ----- 6, 00 3 ==== ==== = |
-------- -------- ---- 26 5, 77 1 ==== ==== = |
| ( ) 20 dit ed At 1 J 14 Au an ua ry |
18, 07 6 |
69 3, 9 54 |
4, 114 |
( ) 70 0, 00 9 |
160 08 9 , |
2, 89 7 |
178 6 71 , |
99 1, 1 |
180 70 7 , |
| al c he nsi inc Tot om pre ve om e: |
-------- -------- --- |
-------- -------- ------ |
-------- -------- ----- |
-------- -------- ------- |
-------- -------- ----- |
-------- -------- ----- |
-------- -------- ----- |
-------- -------- ----- |
-------- -------- ---- |
| fit for th od Pro eri e p |
- | - | - | - | 44 50 6 , |
- | 44 50 6 , |
1, 124 |
45 63 0 , |
| To tal reh siv e i co mp en nco me |
-------- -------- --- - |
-------- -------- ------ - |
-------- -------- ----- - |
-------- -------- ------- - |
-------- -------- ----- 44 50 6 , |
-------- -------- ----- - |
-------- -------- ----- 44 50 6 , |
-------- -------- ----- 1, 124 |
-------- -------- ---- 45 63 0 , |
| cti ith f th e C Tra nsa on s w ow ne rs o om pa ny : ibu tio nd di ibu tio Co ntr str |
|||||||||
| n a ns: led sh -ba sed Eq uit ett ent y s are pa ym |
- | 54 9 |
54 9 |
54 9 |
|||||
| ide nd aid (re fer 12) Div te s p no |
- | - - |
- - |
- - |
- ( ) 17, 69 9 |
- | ( ) 17, 69 9 |
- - |
( ) 17, 69 9 |
| 4 ( ) At 30 Jun e 2 01 Un dit ed au |
-------- -------- --- 18, 07 6 |
-------- -------- ------ 69 3, 54 9 |
-------- -------- ----- 4, 114 |
-------- -------- ------- ( ) 70 0, 00 9 |
-------- -------- ----- 186 89 6 , |
-------- -------- ----- 3, 44 6 |
-------- -------- ----- 20 6, 07 2 |
-------- -------- ----- 3, 11 5 |
-------- -------- ---- 20 9, 187 |
| ==== ==== = |
==== ==== == |
==== ==== = |
==== ==== == |
==== ==== = |
==== ==== = |
==== ==== = |
==== ==== = |
==== ==== = |
The notes on pages 13 to 23 form an integral part of these condensed consolidated interim financial statements.
For six month period ended 30 June 2015
| For the six month | For the six month | ||
|---|---|---|---|
| period ended | period ended | ||
| 30 June 2015 | 30 June 2014 | ||
| USD'000 | USD'000 | ||
| Note | (Unaudited) | (Unaudited) | |
| Operating activities | |||
| Profit for the period before tax | 44,880 | 45,630 | |
| Adjustments for: | |||
| Depreciation and amortisation | 8,244 | 5,450 | |
| Other non-cash items | 637 | 154 | |
| Finance costs | 632 | 653 | |
| Interest income | (320) | (255) | |
| Employee benefit charge | 14 | 2,352 | 1,987 |
| Acquisition costs | 507 | 94 | |
| Net equity-settled share-based payment transactions | (23) | 549 | |
| Provision for bad debts on other receivables | 113 | 254 | |
| Net cash from operating activities | --------------------- 57,022 |
--------------------- 54,516 |
|
| Change in inventories | 409 | (3,850) | |
| Change in trade and other receivables | 8 | (8,890) | (18,853) |
| Change in amounts due from a related party | 7(d) | 730 | (255) |
| Change in trade and other payables | 13 | (10,258) | 12,300 |
| Change in amounts due to related parties | 7(c) | 19 | 972 |
| Prepaid lease rent | 8 | - | (2,725) |
| Cash generated from operations | --------------------- 39,032 |
--------------------- 42,105 |
|
| Employee benefits paid | 14 | (1,612) | (899) |
| Net cash generated from operating activities | --------------------- 37,420 |
--------------------- 41,206 |
|
| Investing activities | --------------------- | --------------------- | |
| Interest received | 171 | 211 | |
| Short term deposit | (163) | (13,624) | |
| Payment for property and equipment | (21,128) | (10,600) | |
| Payment for intangible assets | 5 | (1,897) | (3,103) |
| Investment in subsidiary, net of cash acquired | 20 | (1,618) | (30,407) |
| Payment for acquisition costs | (507) | (94) | |
| Proceeds from sale of property and equipment | 8 | - | |
| --------------------- | --------------------- | ||
| Net cash used in investing activities | (25,134) --------------------- |
(57,617) --------------------- |
|
| Financing activities | |||
| Interest paid | (632) | (653) | |
| Dividend paid to non-controlling interest | 11 | (1,621) | - |
| Dividend paid | 12 | (15,703) | (17,699) |
| Net cash used in financing activities | --------------------- (17,956) |
--------------------- (18,352) |
|
| Net decrease in cash and cash equivalents | --------------------- (5,670) |
--------------------- (34,763) |
|
| Cash and cash equivalents at the beginning of the period | 82,881 | 107,484 | |
| --------------------- | --------------------- | ||
| Cash and cash equivalents at the end of the period | 9 | 77,211 ========== |
72,721 ========== |
The notes on pages 13 to 23 form an integral part of these condensed consolidated interim financial statements.
Al Noor Hospitals Group Plc (the "Company" or "Parent'') is a Company which was incorporated in England and Wales on 20 December 2012. The Company is a public limited liability company operating mainly in the United Arab Emirates ("UAE"). The address of the registered office of the Company is C/O Capita Company Secretarial Services, 1st Floor, 40 Dukes Place, London, EC3A 7NH. The registered number of the Company is 8338604. There is no ultimate controlling party.
The activities of the subsidiaries are the operation of medical hospitals and clinics and the sale of pharmaceuticals, medical supplies and related equipment. These condensed consolidated interim financial statements include the financial performance and position of the Company and its subsidiaries (collectively referred to as "the Group").
The condensed consolidated interim financial statements were authorised for issue by the directors on 24 August 2015. The financial statements are unaudited but have been reviewed by KPMG LLP.
The condensed interim financial statements do not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006.
The figures for the 6 months ended 30 June 2015 and 30 June 2014 are unaudited. Those accounts have been reported on by the Company's auditors and delivered to the Registrar of Companies. The report of the auditors was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report and (iii) did not contain a statement under Section 498 (2) or (3) of the Companies Act 2006.
These condensed consolidated interim financial statements have been prepared in accordance with the International Accounting Standard 34 "Interim Financial Reporting" as endorsed by the European Union. They do not include all of the information required for full annual financial statements, and should be read in conjunction with the financial statements published as at and for the year ended 31 December 2014.
These condensed consolidated interim financial statements have been prepared on the going concern basis. At 30 June 2015, the Group had net assets amounting to USD 265,771 thousand. The Group is profitable and cash generative and the Directors have considered the Group's cash forecasts for a period of 12 months from the signing of the balance sheet. In addition, the Group has access to an undrawn committed borrowing facility of up to USD 81.7 million. The Directors have a reasonable expectation that the Group has adequate resources to meet its liabilities as they fall due for at least 12 months from the date of approval of these condensed consolidated interim financial statements. Thus, they continue to adopt the going concern basis in preparing the financial information.
The condensed consolidated interim financial statements have been prepared on the historical cost basis except where adopted IFRS mandates that fair value accounting is required.
These condensed consolidated interim financial statements and financial information are presented in United States Dollar (USD), rounded to the nearest thousand. The functional currency of the majority of the Group's entities is the United Arab Emirates Dirham (AED) and is the currency of the primary economic environment in which the Group operates. The United Arab Emirates Dirham (AED) is currently pegged against the United States Dollar (USD) at a rate of 3.67 per US Dollar.
There are no material changes in management judgments, estimates and assumptions during the six month period ended 30 June 2015 from the annual financial statements published for the year ended 31 December 2014.
The accounting policies applied by the Group in this condensed consolidated interim financial report are the same as those applied by the Group in its published consolidated financial statements as at and for the year ended 31 December 2014 which were prepared in accordance with IFRS as adopted by the European Union.
A number of amendments to standards were effective for the first time for the Group from 1 January 2015 and have been applied in preparing these condensed consolidated interim financial statements. None of these amendments had an impact on these condensed consolidated interim financial statements.
New standards, amendments to standards and interpretations that are not yet effective for the period ended 30 June 2015 have not been applied in preparing these condensed consolidated interim financial statements. None of these is expected to have a significant effect on the Group, except for the following which could change the classification and measurement of the financial assets. The full extent of the impact has not yet been determined.
During the six month period ended 30 June 2015, the Group acquired property and equipment with a cost of USD 22,701 thousand (six month period ended 30 June 2014: USD 10,600 thousand). The depreciation for the period ended 30 June 2015 was USD 7,559 thousand (six month period ended 30 June 2014: USD 5,240 thousand).
| 30 June | 31 December | |
|---|---|---|
| 2015 | 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Audited) | |
| Goodwill | 22,046 | 22,046 |
| Software cost | 8,899 | 7,825 |
| Software under development | 3,444 | 3,306 |
| ---------------------- 34,389 |
--------------------- 33,177 |
|
| ========== | ========== |
The Group formally reviews the carrying value of goodwill annually, when the Group prepares its budget and strategic planning.
Software under development of USD 1,509 thousand (six month ended 30 June 2014, USD 7,423 thousand) has been completed and transferred to the software cost category. The Group has also acquired software amounting to USD 1,897 thousand (six month ended 30 June 2014, USD 3,103 thousand). The amortisation for the period ended 30 June 2015 was USD 685 thousand (six month period ended 30 June 2014: USD 210 thousand).
| 30 June | 31 December | |
|---|---|---|
| 2015 | 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Audited) | |
| Pharmacy items | 13,207 | 13,066 |
| Consumables | 6,414 | 7,360 |
| Less: allowance for inventory obsolescence | ---------------------- 19,621 (197) |
---------------------- 20,426 (41) |
| ---------------------- | ---------------------- | |
| 19,424 | 20,385 | |
| ========== | ========== |
Related parties comprise the parent, the ultimate parent, the Shareholders, key management personnel and those entities over which the parent, the ultimate parent, the directors or the Group can exercise significant influence or which can significantly influence the Group. In the ordinary course of business, the Group receives goods and services from, and provides goods and services to, such entities on rates, terms and conditions agreed upon by management.
The compensation of key management personnel during the period was as follows:
| For the six month period ended 30 June 2015 USD'000 (Unaudited) |
For the six month period ended 30 June 2014 USD'000 (Unaudited) |
|
|---|---|---|
| Salaries and short-term benefits* | 3,239 ========= |
2,150 ========= |
| Directors' emoluments | 512 ========= |
446 ========= |
| End of service benefits | 126 ========= |
60 ========= |
| Net equity-settled share-based payment transactions |
(23) ========= |
549 ========= |
*Key management personnel include C level executives and hospital directors.
| For the six month | For the six | |
|---|---|---|
| month | ||
| period ended | period ended | |
| 30 June 2015 | 30 June 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Unaudited) | |
| Rent expenses | 7,667 ========== |
6,170 ========== |
| Purchases | 4,004 ========== |
3,859 ========== |
| Revenue | 211 ========== |
255 ========== |
| 30 June 2015 USD'000 (Unaudited) |
31 December 2014 USD'000 (Audited) |
|---|---|
| 3,753 | |
| 1,914 | |
| 266 | |
| 213 | |
| 173 | 4 |
| 6,169 | ---------------------- 6,150 ========== |
| 3,512 1,833 278 373 ---------------------- ========== |
The above amounts due to related parties are non-interest bearing and repayable on demand.
| 30 June | 31 December | |
|---|---|---|
| 2015 | 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Audited) | |
| Amount due from a shareholder | 121 | 851 |
| ========== | ========== |
| 30 June | 31 December | |
|---|---|---|
| 2015 | 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Audited) | |
| Trade receivables | 106,099 | 98,049 |
| Staff advances and other receivables | 8,687 | 10,059 |
| Prepayments* | 11,995 | 9,801 |
| ---------------------- 126,781 |
---------------------- 117,909 |
|
| Within one year | ========== 124,301 |
========== 115,375 |
| After one year* | 2,480 | 2,534 |
| ---------------------- 126,781 |
---------------------- 117,909 |
|
| ========== | ========== |
*This includes prepaid lease rent for the Gulf International Cancer Centre for the period of 24 years amounting to USD 2,589 thousand (2014:USD 2,725 thousand).
| 30 June | 31 December | |
|---|---|---|
| 2015 | 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Audited) | |
| Cash in hand | 466 | 331 |
| Cash at bank | 29,541 | 60,523 |
| Term deposit* | 47,204 | 22,027 |
| ---------------------- 77,211 |
---------------------- 82,881 |
|
| ========== | ========== |
*The average effective interest rate on term deposits is 1.1% (31 December 2014: 1.1%) per annum and the maturity date of these term deposits is less than 3 months.
| 30 June | 31 December | |
|---|---|---|
| 2015 | 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Audited) | |
| Fixed deposit | 13,787 | 13,624 |
| ========== | ========== |
The maturity date of this deposit is more than 3 months from the start of the term and the average effective interest rate on the deposit is 1.08% (31 December 2014: 1.14%).
| Share capital | 30 June 2015 USD'000 (Unaudited) |
31 December 2014 USD'000 (Audited) |
|---|---|---|
| Issued and fully paid 116,866,203 shares of GBP 10 pence each (converted to USD at 1.5467) |
18,076 ========= |
18,076 ======== |
| Non-controlling interest | 30 June 2015 USD'000 (Unaudited) |
31 December 2014 USD'000 (Audited) |
| At the beginning of the period / year Share of results for the period / year Dividend paid |
4,800 2,824 (1,621) ------------------ |
1,991 2,809 - ----------------- |
| At the end of the period / year | 6,003 ========= |
4,800 ======== |
The Group paid dividends to Shareholders as set out below:
| For the six month | For the six month | |
|---|---|---|
| period ended | period ended | |
| 30 June 2015 | 30 June 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Unaudited) | |
| Dividend paid | 15,703 | 17,699 |
| ============ | ============ |
The Board determined on 24 August 2014 that an interim dividend of GBP 4.1 pence for 2015 be paid. The dividend will be paid on 5 October 2015 to all ordinary shareholders who were on the register of members at the close of business on 4 September 2015. This dividend has not been recognised as a liability at the balance sheet date.
| 30 June | 31 December | |
|---|---|---|
| 2015 | 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Audited) | |
| Trade payables | 36,727 | 41,071 |
| Accrued liabilities | 20,920 | 24,488 |
| Other payables | 438 | 1,211 |
| Amounts payable for investment in subsidiaries | - | 1,618 |
| ------------------ | ----------------- | |
| 58,085 | 68,388 | |
| ========= | ======== | |
| Trade and other payables are repayable as follows: | ||
| Within one year | 58,085 | 67,792 |
| After one year | - | 596 |
| ------------------ | ----------------- | |
| 58,085 | 68,388 | |
| ========= | ======== |
During the period ended 30 June 2015, an amount of USD 2,352 thousand has been accrued for the end of service benefits (for the six months period ended 30 June 2014: USD 1,987 thousand). Further, the Group has paid an amount of USD 1,612 thousand for the period ended 30 June 2015 ((for the six months period ended 30 June 2014: USD 899 thousand) for termination benefits.
| For the six month | For the six month | |
|---|---|---|
| period ended | period ended | |
| 30 June 2015 | 30 June 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Unaudited) | |
| Inpatient | 54,212 | 50,498 |
| Outpatient | 189,759 | 174,283 |
| ----------------- | ----------------- | |
| 243,971 | 224,781 | |
| ======== | ======== |
Revenue is stated after potential insurance claim rejections and discounts provided to insurance companies. Management estimates these claim rejections based on historic actual data and trends, its experience in dealing with insurance companies and the current economic environment. The actual rejected claims in the past have not differed materially from those estimated by management.
| For the six month | For the six month | |
|---|---|---|
| period ended | period ended | |
| 30 June 2015 | 30 June 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Unaudited) | |
| Revenue from rendering of services | 209,655 | 191,943 |
| Revenue from sale of goods | 34,316 | 32,838 |
| ----------------- | ----------------- | |
| 243,971 | 224,781 |
======== ========
Notes to the condensed consolidated interim financial statements
The Group defends various legal claims raised against it in the normal course of business. Where it considers that it is probable that it will settle a claim, management estimate the likely amount of settlement and provide accordingly. Claims that are considered remote or only possible represent contingent liabilities of the Group. If the Group's defence against these contingent liabilities is not successful, the Group may ultimately become liable for settlement. The Group's Medical Malpractice Insurance Policy covers all settlements made by the Group subject to insurance deductibles and the overall coverage provided by the policy. The Board of Directors and Management do not expect actions arising from the claims currently classified as contingent liabilities to have a material effect on the Group's future financial position.
The calculation of basic earnings per share at 30 June 2015 was based on the profit attributable to the ordinary shareholders of USD 42,056 thousand (30 June 2014: USD 44,506 thousand) and a weighted average number of ordinary shares outstanding of 116,866 thousand (30 June 2014: 116,866).
The calculation of diluted earnings per share at 30 June 2015 was based on the profit attributable to the ordinary shareholders of USD 42,056 thousand (30 June 2014: USD 44,506 thousand) and a diluted weighted average number of ordinary shares outstanding of 117,232 thousand (30 June 2014: 117,232 thousand).
The Group's operations are not subject to any material seasonal variation.
The Group has the following major reportable segments, which are the Group's strategic business units for which the Group's CODM reviews internal management reports. The Group operates in the Emirate of Abu Dhabi, Dubai and the Sultanate of Oman and the following summary describes the operations in each of the Group's reportable segments:
| Reportable segments Central region |
Operations Operation of hospitals, clinics and pharmacies in Abu Dhabi. The hospitals cater to both inpatient and outpatient care. |
|---|---|
| Western and Eastern region | Operation of hospitals, clinics and pharmacies in Abu Dhabi. The hospitals cater to both inpatient and outpatient care. |
| International | Operation of clinic and pharmacies in the Sultanate of Oman. The clinic caters to outpatient care. |
| Northern Emirates | Operation of clinic and physiotherapy in Dubai. The clinic |
caters to outpatient care.
Performance is measured based on segment profit as included in the internal management reports that are reviewed by the Group's CODM. Segment profit is used to measure performance as management believes that such information is most relevant in evaluating the results of each segment.
| Central region USD'000 |
Western and eastern region USD'000 |
International USD'000 |
Northern Emirates USD'000 |
Total USD'000 |
|
|---|---|---|---|---|---|
| 30 June 2015 (Unaudited) | |||||
| Revenue | 165,794 | 77,446 | 156 | 547 | 243,943 |
| Net profit / (loss) | 32,803 | 24,266 | (541) | (670) | 55,858 |
| 30 June 2014 (Unaudited) | |||||
| Revenue | 159,887 | 63,963 | 119 | 768 | 224,737 |
| Net profit / (loss) | 38,357 | 18,188 | (590) | 53 | 56,008 |
| For the six month | For the six month | |
|---|---|---|
| period ended | period ended | |
| 30 June 2015 | 30 June 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Unaudited) | |
| Revenue | ||
| Total revenue for reportable segment | 243,943 | 224,737 |
| Other revenue | 28 | 44 |
| ----------------- | ----------------- | |
| Total revenue for the period | 243,971 | 224,781 |
| ======== | ======== |
| For the six month | For the six month | |
|---|---|---|
| period ended | period ended | |
| 30 June 2015 | 30 June 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Unaudited) | |
| Net profit | ||
| Total net profit for reportable segments | 55,858 | 56,008 |
| Other income | 28 | 44 |
| Interest income | 379 | 320 |
| Corporate shared services | (9,017) | (7,075) |
| Un-allocated corporate expenses: | ||
| Depreciation | (252) | (291) |
| Interest expenses | (419) | (671) |
| Other expenses | (1,697) | (2,705) |
| Net profit for the period | ----------------- 44,880 |
----------------- 45,630 |
| For the six month | For the six month | |
|---|---|---|
| period ended | period ended | |
| 30 June 2015 | 30 June 2014 | |
| USD'000 | USD'000 | |
| (Unaudited) | (Unaudited) | |
| Cash paid for purchase of GICC | - | 21,798 |
| Cash paid for deferred consideration on | ||
| acquisition of Al Madar | 1,618 | 9,111 |
| Less: cash and cash equivalents acquired | - | (502) |
| Total Cash Outflow | __ 1,618 |
__ 30,407 |
| ======== | ======== |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.